Peer-influenced content. Sources you trust. No registration required. This is HCN.
GoodRx for Healthcare Professionals
Prescription drug prices rise each year in January and July. As we start off the new year, GoodRx Health is reporting that a total of 658 branded drugs have just had their prices increased an average of 4.9%, while 11 generic medications have seen their prices rise an average of 10.3%. That’s less than the 832 drugs that saw their price increase in January 2021. Among the biggest movers are Nucynta, paclitaxel, and Prilosec.
All Specialties January 12th 2022
Amy Watson became famous for coining the term “COVID long hauler” to describe people, such as herself, who suffer from the effects of the respiratory disease over an extended period. These long-haul symptoms can include fever, body aches, and fatigue. Watson herself says she rarely goes more than a few hours without suffering a fever, nearly two years after first contracting COVID-19. GoodRx Health chronicles Amy Watson’s story and what it’s like for people suffering from long COVID.
Allergy & Immunology December 14th 2021
At the outset of the pandemic, biotechnology company Novavax was one of the frontrunners to bring a vaccine against COVID-19 to market. But nearly two years later, Novavax’s vaccine has yet to appear. In a compelling article, the BMJ details the repeated delays and setbacks that have torpedoed Novavax’s once-promising vaccine candidate and rendered it unnecessary now that other vaccines from Pfizer, Moderna, and AstraZeneca flood the global marketplace.
Only 8 of 35 studies could be included in the meta-analysis. Combined, these indicate a 25% risk reduction for physical distancing, 53% for mask-wearing, and 53% for hand washing. The accompanying BMJ editorial explores the possible reasons for the findings and the oddity that so little quality research is available on such an important topic.
Family Medicine/General Practice November 30th 2021
JAMA Network
In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health care, and health policy efforts.
Hematology April 14th 2021